{
    "nct_id": "NCT04736472",
    "official_title": "Implementing Pharmacogenetic Testing in Gastrointestinal Cancers",
    "inclusion_criteria": "1. Able and willing to provide informed consent\n2. Male or female, aged 18 years or older at the time of study initiation\n3. Pathologically confirmed gastrointestinal malignancy for which treatment with a fluoropyrimidine and/or irinotecan is indicated\n4. Willing to undergo blood or saliva sampling for PGx testing and comply with all study-related procedures\n5. Life expectancy of at least 6 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with irinotecan\n2. DPYD or UGT1A1 genotype already known\n3. Severe renal or hepatic impairment (or unacceptable laboratory values), including:\n\n   * Neutrophil count of <1.5 x 109/L, platelet count of <100 x 109/L\n   * Hepatic function as defined by serum bilirubin >1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) >2.5 x ULN, or in case of liver metastases ALT and AST>5 x ULN\n   * Renal function as defined by serum creatinine >1.5 x ULN, or creatinine clearance <60 ml/min (by Cockcroft-Gault Equation)\n4. Women who are pregnant or breast feeding, or subjects who refuse to use reliable contraceptive methods throughout the study\n5. Treating physician does not want subject to participate",
    "miscellaneous_criteria": ""
}